The startup utilizes proprietary circulating tumor cell (CTC) technology to enhance the detection and monitoring of cancer progression. This approach enables healthcare providers to track tumor cell dynamics more effectively, improving patient management and treatment outcomes.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting and monitoring cancer progression, such as imaging and invasive biopsies, have limitations in early detection and real-time tracking of metastasis. The inability to effectively monitor circulating tumor cells (CTCs) hinders timely intervention and personalized treatment strategies.
Solution
TellBio's TellDx CTC System is a microfluidic diagnostic platform designed to isolate and analyze viable circulating tumor cells (CTCs) from patient liquid biopsies. This technology enables comprehensive monitoring of cancer progression and metastasis, offering valuable insights into treatment response and resistance mechanisms. By providing a non-invasive method for capturing and studying CTCs, the TellDx platform facilitates the development of personalized treatment strategies and improves patient outcomes. The platform's ability to isolate live CTCs allows for downstream analysis, including drug sensitivity testing and genomic profiling, to identify tailored therapies for patients experiencing disease progression.
Target Audience
The primary target audience includes clinical researchers and pharmaceutical companies focused on developing and implementing personalized cancer therapies, as well as medical centers seeking advanced diagnostic tools for monitoring cancer progression.
Features
- Microfluidic platform for high-efficiency isolation of viable CTCs from liquid biopsies
- Enrichment of CTCs agnostic to the primary solid tumor type
- Enables downstream analysis of CTCs, including genomic profiling and drug sensitivity testing
- Facilitates identification of mechanisms of resistance and sensitivity to various cancer therapies
- Supports personalized treatment strategies based on CTC characteristics
- Deployed as a research tool at centers of excellence